These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
114 related articles for article (PubMed ID: 33237384)
1. Authors' reply to letters to the editor "model-based simulation to support the extended dosing regimens of atezolizumab". Chou CH; Hsu LF Eur J Clin Pharmacol; 2021 Jul; 77(7):1067-1068. PubMed ID: 33237384 [No Abstract] [Full Text] [Related]
2. Letter to the editor: Model-based simulation to support the extended dosing regimens of atezolizumab. Wu B; Liu SN; Ballinger M; Sternheim N; Patel H; Mazieres J; Bruno R Eur J Clin Pharmacol; 2021 Jul; 77(7):1065-1066. PubMed ID: 33415499 [No Abstract] [Full Text] [Related]
3. Alternative dosing regimens for atezolizumab: an example of model-informed drug development in the postmarketing setting. Morrissey KM; Marchand M; Patel H; Zhang R; Wu B; Phyllis Chan H; Mecke A; Girish S; Jin JY; Winter HR; Bruno R Cancer Chemother Pharmacol; 2019 Dec; 84(6):1257-1267. PubMed ID: 31542806 [TBL] [Abstract][Full Text] [Related]
4. Alternative dosing regimens for atezolizumab: right dose, wrong frequency. Goldstein DA; Ratain MJ Cancer Chemother Pharmacol; 2019 Dec; 84(6):1153-1155. PubMed ID: 31630223 [TBL] [Abstract][Full Text] [Related]
5. Letter to the editor: Comments on 'A six-weekly dosing schedule for pembrolizumab in patients with cancer based on evaluation using modelling and simulation'. Diekstra MHM; Malmberg R; Sleijfer S; van Leeuwen RWF Eur J Cancer; 2020 Oct; 138():54-56. PubMed ID: 32854077 [No Abstract] [Full Text] [Related]
6. Reply to Francesco Massari and Vincenzo Di Nunno's Letter to the Editor re: Jose Luis Perez-Gracia, Yohann Loriot, Jonathan E. Rosenberg, et al. Atezolizumab in Platinum-treated Locally Advanced or Metastatic Urothelial Carcinoma: Outcomes by Prior Number of Regimens. Eur Urol 2018;73:462-8. Perez-Gracia JL Eur Urol; 2018 Jul; 74(1):e14. PubMed ID: 29656856 [No Abstract] [Full Text] [Related]
7. Editorial: a clinical decision tool to identify patients who might benefit most from intensified dosing in the biological era-getting nearer? Authors' reply. Dulai PS Aliment Pharmacol Ther; 2020 Apr; 51(7):738-739. PubMed ID: 32162371 [No Abstract] [Full Text] [Related]
8. Atezolizumab plus bevacizumab for unresectable hepatocellular carcinoma - Authors' replys. Lee KH; Lee MS Lancet Oncol; 2020 Sep; 21(9):e413. PubMed ID: 32888463 [No Abstract] [Full Text] [Related]
9. Reply to Satoshi Funada, Takashi Yoshioka, and Yan Luo's Letter to the Editor re: Ashley M. Hopkins, Ganessan Kichenadasse, Christos S. Karapetis, et al. Concomitant Antibiotic Use and Survival in Urothelial Carcinoma Treated with Atezolizumab. Eur Urol 2020;78:540-3. Hopkins AM; Kichenadasse G; Sorich MJ Eur Urol; 2020 Dec; 78(6):e227. PubMed ID: 32958298 [No Abstract] [Full Text] [Related]
10. Atezolizumab and Bevacizumab in Hepatocellular Carcinoma. Reply. Finn RS; Cheng AL N Engl J Med; 2020 Aug; 383(7):695. PubMed ID: 32786201 [No Abstract] [Full Text] [Related]
12. Comparative Effectiveness of Non-cisplatin First-line Therapies for Metastatic Urothelial Carcinoma: Phase 2 IMvigor210 Study Versus US Patients Treated in the Veterans Health Administration. Vander Velde N; Guerin A; Ionescu-Ittu R; Shi S; Wu EQ; Lin SW; Hsu LI; Saum KU; de Ducla S; Wang J; Li S; Thåström A; Liu S; Shi L; Leppert JT Eur Urol Oncol; 2019 Feb; 2(1):12-20. PubMed ID: 30929841 [TBL] [Abstract][Full Text] [Related]
17. Population pharmacokinetics, exposure-safety, and immunogenicity of atezolizumab in pediatric and young adult patients with cancer. Shemesh CS; Chanu P; Jamsen K; Wada R; Rossato G; Donaldson F; Garg A; Winter H; Ruppel J; Wang X; Bruno R; Jin J; Girish S J Immunother Cancer; 2019 Nov; 7(1):314. PubMed ID: 31753029 [TBL] [Abstract][Full Text] [Related]
18. ASPECCT: panitumumab versus cetuximab for colorectal cancer--authors' reply. Price TJ; Peeters M; Ruff P; Murugappan S; Sidhu R Lancet Oncol; 2014 Jul; 15(8):e303. PubMed ID: 24988928 [No Abstract] [Full Text] [Related]
19. Editorial: vedolizumab in pregnancy - is gut selectivity as good for baby as it is for mum? Authors' reply. Mahadevan U; Vermeire S; Lasch K; Abhyankar B; Bhayat F; Blake A; Dubinsky M Aliment Pharmacol Ther; 2017 May; 45(9):1284. PubMed ID: 28370036 [No Abstract] [Full Text] [Related]
20. Why is survival after pembrolizumab affected by previous radiotherapy? - Authors' reply. Lee P; Shaverdian N Lancet Oncol; 2017 Sep; 18(9):e505. PubMed ID: 28884693 [No Abstract] [Full Text] [Related] [Next] [New Search]